Global Sarcopenia Treatment Market to Reach USD 4.7 Billion by 2035 at 4.9% CAGR: Growth Fueled by Aging Population, Diagnostic Advances, and Nutritional Supplement Demand

The global sarcopenia treatment market is undergoing a period of steady and strategic expansion, driven by demographic transformations, improved diagnostic capabilities, and a surge in interest surrounding preventive health and healthy aging. Valued at US$ 2.8 Billion in 2024, the market is projected to reach US$ 4.7 Billion by 2035, reflecting a CAGR of 4.9% from 2025 to 2035. As the world's population increasingly moves into older age brackets, the prevalence of age-related muscle loss continues to rise, triggering demand for both nutritional and emerging pharmaceutical interventions.

Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28547

Market Overview

Sarcopenia refers to the progressive decline of muscle mass, strength, and function, predominantly associated with aging. While lifestyle modifications such as exercise and nutrition remain foundational treatment strategies, technological advancements in diagnostics-particularly DXA scans and bioelectrical impedance analysis-have sharply improved the ability to detect the condition earlier.

This earlier detection has created a growing market for nutritional support products and investigational therapies. Although there is no FDA-approved drug specifically for sarcopenia, the pipeline for pharmacological interventions is expanding quickly, suggesting strong future potential.

In 2024, the market was largely dominated by nutritional supplements, which held 74.3% of the revenue share, driven by widespread adoption and low cost. Regionally, North America accounted for 39.5% of the global market, owing to high awareness and well-established diagnostic practices.

Market Size and Forecast

By rising from US$ 2.8 Billion (2024) to US$ 4.7 Billion (2035), the sarcopenia treatment market demonstrates consistent and long-term opportunity. The CAGR of 4.9% from 2025-2035 reflects not only increased identification of at-risk patients but also growing acceptance of multimodal treatment strategies that integrate nutrition, exercise, and emerging pharmaceuticals.

Furthermore, the proportion of adults aged 60 and above worldwide is expected to double between 2020 and 2050, significantly elevating demand for sarcopenia intervention and prevention solutions.

Key Market Growth Drivers

1. Increased Awareness and Diagnosis
Public health campaigns, aging research initiatives, and healthcare provider education are contributing to higher diagnosis rates. Improved tools such as DXA and muscle function testing enable faster and more accurate identification, facilitating early treatment and preventing advanced muscle deterioration.

2. Growing Adoption of Nutritional Supplementation
Nutritional supplements-including protein powders, leucine-based amino acid blends, vitamin D, calcium, and other essential micronutrients-are now widely recommended to older adults, making them the largest revenue contributor in the market. Their low cost, accessibility, and integration into clinical care make them a cornerstone of sarcopenia management.

3. Emergence of Pharmacological Therapies
New therapies such as myostatin inhibitors, SARMs (Selective Androgen Receptor Modulators), and 15-PGDH inhibitors are showing promising results in clinical research. These treatments aim to provide targeted muscle growth and improved physical performance, potentially shifting the market dynamic post-2030.

Analysis of Key Players - Strategies Driving Market Influence
Leading companies include Eli Lilly and Company, Pfizer Inc., Amgen Inc., Nestlé Health Science, Abbott Nutrition, and several emerging biotech innovators such as Biophytis, TNF Pharmaceuticals, Epirium Bio, and Rejuvenate Biomed.

Common strategies among these key players include:

1. Heavy Investment in R&D for Breakthrough Therapies
Pharmaceutical firms are accelerating research into muscle growth agents such as:

• Myostatin pathway inhibitors
• SARMs
• 15-PGDH inhibitors
• Hormone-based therapies

These innovations reflect the growing need for therapeutic options that go beyond exercise and nutrition.

2. Expansion of Nutritional Supplement Portfolios
Companies like Nestlé Health Science and Abbott Nutrition continue dominating the supplement segment by developing scientifically backed formulations with enhanced absorption, branched-chain amino acids, and vitamin D fortification.

3. Collaborations with Research Institutions
Biotech companies are forming partnerships with universities, health systems, and research organizations to accelerate clinical validation and regulatory approval.

4. Geographic Expansion in High-Growth Markets
Major players are focusing on the Asia-Pacific region, which is expected to see the fastest growth due to its rapidly aging population and expanding healthcare access.

Market Challenges and Opportunities

Key Challenges

1. Lack of FDA-Approved Pharmacological Treatments:
While several promising drugs are in trials, regulatory approval remains a hurdle.

2. Limited Reimbursement Policies:
Nutritional supplements are often not covered by insurance, restricting adoption among lower-income populations.

3. Difficulty in Diagnosing Early-Stage Sarcopenia:
Although diagnostics are improving, sarcopenia remains underdiagnosed globally.

Key Opportunities

1. Digital Health Integration:
Wearables, AI-driven diagnostics, and personalized exercise programs offer enormous growth potential.

2. Aging Populations in APAC and Europe:
Countries with rapidly aging demographics, such as Japan, South Korea, and Italy, present lucrative growth opportunities.

3. Combination Therapies:
Future treatment models may combine pharmaceuticals with nutrition and exercise, raising treatment efficacy and market spending.

Recent Developments

• In March 2025, TNF Pharmaceuticals, Inc. announced that data from the Phase 2a clinical trial of its oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International Conference on Frailty and Sarcopenia Research (ICFSR) held March 12-14, 2025, in Toulouse, France.

• In March 2025, Allosteric Bioscience, Inc. (ABI), announced that it had licensed technology from Johns Hopkins University for the treatment or prevention of sarcopenia, which is a serious medical condition involving the loss of muscle mass, quality, and strength and is a significant part of the natural aging process. Sarcopenia can result in reduced quality of life due to falls, bone fractures, and disability.

• In January 2025, Epirium Bio, Inc. announced that it has initiated dosing of healthy volunteers in its Phase 1 dose-escalation clinical trial of MF-300, an investigational, first-in-class, orally administered,15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in development for the treatment of sarcopenia, or age-induced muscle weakness.

Explore Strategies & Trends - Request Full Report Access - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28547

Market Segmentations

By Treatment Type

• Nutritional supplements (dominant segment, 74.3% in 2024)
• Protein supplements
• Amino acid supplements
• Vitamin D & calcium supplements
• Vitamin B12 & folate supplements
• Pharmaceuticals including hormone therapy, ACE inhibitors, SARMs, and others

By Route of Administration
• Oral
• Parenteral
• Others

By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region
• North America leads the market and is expected to maintain dominance through 2035 due to high healthcare spending and diagnostic rates.

• Asia-Pacific is projected to be the fastest-growing region driven by rapidly aging populations, rising healthcare access, and increasing penetration of nutritional and pharmaceutical products.

• Europe continues to be a robust market, particularly in Western and Northern Europe where aging demographics are significantly influencing healthcare demands.

• Latin America and Middle East & Africa remain emerging markets, expected to grow with increased healthcare modernization and awareness initiatives.
Investment Landscape and ROI Outlook

Investment activity in the sarcopenia treatment market is accelerating, especially across:

• Clinical-stage biotech firms developing next-generation therapies
• Nutritional supplement companies expanding their geriatric formulation portfolios
• Diagnostic technology developers
• Digital health and AI-based wellness platforms

Investors can expect moderate but stable ROI, with the potential for high return in segments tied to pharmaceutical breakthroughs. As the first FDA-approved drug for sarcopenia draws nearer (expected around early-2030s), investment returns may sharply increase.

Analysts' Viewpoint

Analysts agree that the future of the sarcopenia treatment market hinges on several key forces:

• An aging population that will nearly double by 2050
• Growing awareness and better diagnostics
• Mainstream acceptance of nutritional supplementation
• Development of advanced pharmacological therapies

While lifestyle interventions remain critical, the long-term growth of the market depends heavily on successful clinical trials and drug approvals, alongside improved reimbursement guidelines. Digital health integration and combination therapies will likely shape the next decade of market evolution.

Why Buy This Report?

Purchase of this report offers:

• Comprehensive analysis of market drivers, restraints, and opportunities
• Forecast insights up to 2035, including CAGR and revenue projections
• Detailed segmentation by region, treatment type, and distribution channel
• Competitive intelligence covering major players and emerging innovators
• Insights into regulatory outlook and drug pipeline development
• Coverage of recent clinical research, partnerships, and technological advancements
• Strategic guidance for investors, healthcare providers, and product developers

FAQs

1. How big was the global sarcopenia treatment market in 2024?
It was valued at US$ 2.8 Billion in 2024.
2. What is the projected size of the market by 2035?
It is expected to reach more than US$ 4.7 Billion by 2035.
3. What factors are driving growth in the sarcopenia treatment market?
Key drivers include increased awareness and diagnosis, greater adoption of nutritional supplementation, and the emergence of pharmacological therapies.
4. What is the expected CAGR from 2025 to 2035?
The industry is projected to grow at a CAGR of 4.9%.
5. Which region dominates the market?
North America is expected to lead the market throughout the forecast period.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=28547<ype=S

Explore Latest Research Reports by Transparency Market Research:

Exosome Isolation Market: https://www.transparencymarketresearch.com/exosome-isolation-market.html
Soft Mist Inhalers Market: https://www.transparencymarketresearch.com/soft-mist-inhalers-market.html
Coronary Stents Market: https://www.transparencymarketresearch.com/coronary-stents-market.html

Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.